ASCO 2015: Dr. Walter M. Stadler gives his top picks in genitourinary research

Dr. Walter M. Stadler picks the upcoming ASCO presentations he anticipates to be the most interesting in genitourinary research.

• 4501 A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).

• 4502 Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012.

• 4505 A phase II/III, double-blind, randomized trial comparing maintenance lapatinib with placebo after first-line chemotherapy in HER1/2 positive metastatic bladder cancer patients.

• 4509 Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): Results from RECORD-3.

• 4516Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).

• 5001Docetaxel and/or zoledronic acid for hormone-naive prostate cancer: First overall survival results from STAMPEDE (NCT00268476). The Oncology Report covered this study following a pre-meeting press conference.

• LBA5002A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521).

• 5000The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC).

• 5003Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).

• 5004Defining a molecular subclass of treatment resistant prostate cancer.

• 5007 TROG 03.06 and VCOG PR 01-03: The “timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)” collaborative randomized phase III trial.

Dr. Walter M. Stadler is the Fred C. Buffett Professor of Medicine and Surgery; associate dean for clinical research; chief, section of hematology/oncology; and director, genitourinary program, University of Chicago.

Dr. Walter M. Stadler picks the upcoming ASCO presentations he anticipates to be the most interesting in genitourinary research.

• 4501 A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).

• 4502 Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012.

• 4505 A phase II/III, double-blind, randomized trial comparing maintenance lapatinib with placebo after first-line chemotherapy in HER1/2 positive metastatic bladder cancer patients.

• 4509 Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): Results from RECORD-3.

• 4516Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).

• 5001Docetaxel and/or zoledronic acid for hormone-naive prostate cancer: First overall survival results from STAMPEDE (NCT00268476). The Oncology Report covered this study following a pre-meeting press conference.

• LBA5002A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521).

• 5000The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC).

• 5003Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).

• 5004Defining a molecular subclass of treatment resistant prostate cancer.

• 5007 TROG 03.06 and VCOG PR 01-03: The “timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)” collaborative randomized phase III trial.

Dr. Walter M. Stadler is the Fred C. Buffett Professor of Medicine and Surgery; associate dean for clinical research; chief, section of hematology/oncology; and director, genitourinary program, University of Chicago.

Dr. Walter M. Stadler picks the upcoming ASCO presentations he anticipates to be the most interesting in genitourinary research.

• 4501 A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).

• 4502 Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012.

• 4505 A phase II/III, double-blind, randomized trial comparing maintenance lapatinib with placebo after first-line chemotherapy in HER1/2 positive metastatic bladder cancer patients.

• 4509 Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): Results from RECORD-3.

• 4516Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).

• 5001Docetaxel and/or zoledronic acid for hormone-naive prostate cancer: First overall survival results from STAMPEDE (NCT00268476). The Oncology Report covered this study following a pre-meeting press conference.

• LBA5002A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521).

• 5000The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC).

• 5003Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).

• 5004Defining a molecular subclass of treatment resistant prostate cancer.

• 5007 TROG 03.06 and VCOG PR 01-03: The “timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)” collaborative randomized phase III trial.

Dr. Walter M. Stadler is the Fred C. Buffett Professor of Medicine and Surgery; associate dean for clinical research; chief, section of hematology/oncology; and director, genitourinary program, University of Chicago.